Trends and Outcomes of Off-label Use of Transcatheter Aortic Valve Replacement: Insights From the NCDR STS/ACC TVT Registry

IMPORTANCE: Transcatheter aortic valve replacement (TAVR) was approved by the US Food and Drug Administration for severe aortic stenosis in patients who cannot undergo surgery and for patients at high operative risk. Use of TAVR for off-label indications has not been previously reported. OBJECTIVE:...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:JAMA Cardiol
Auteurs principaux: Hira, Ravi S., Vemulapalli, Sreekanth, Li, Zhuokai, McCabe, James M., Rumsfeld, John S., Kapadia, Samir R., Alam, Mahboob, Jneid, Hani, Don, Creighton, Reisman, Mark, Virani, Salim S., Kleiman, Neal S.
Format: Artigo
Langue:Inglês
Publié: American Medical Association 2017
Sujets:
Original Investigation
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5710589/
https://ncbi.nlm.nih.gov/pubmed/28636718
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2017.1685
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires